Identifying diagnostic and prognostic factors in cerebral amyloid angiopathy‐related inflammation: A systematic analysis of published and seven new cases

Aims Cerebral amyloid angiopathy (CAA)‐related inflammation (CAA‐RI) is a potentially reversible manifestation of CAA, histopathologically characterised by transmural and/or perivascular inflammatory infiltrates. We aimed to identify clinical, radiological and laboratory variables capable of improvi...

Full description

Saved in:
Bibliographic Details
Published inNeuropathology and applied neurobiology Vol. 50; no. 1; pp. e12946 - n/a
Main Authors Szalardy, Levente, Fakan, Bernadett, Maszlag‐Torok, Rita, Ferencz, Emil, Reisz, Zita, Radics, Bence L., Csizmadia, Sandor, Szpisjak, Laszlo, Annus, Adam, Zadori, Denes, Kovacs, Gabor G., Klivenyi, Peter
Format Journal Article
LanguageEnglish
Published England 01.02.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Aims Cerebral amyloid angiopathy (CAA)‐related inflammation (CAA‐RI) is a potentially reversible manifestation of CAA, histopathologically characterised by transmural and/or perivascular inflammatory infiltrates. We aimed to identify clinical, radiological and laboratory variables capable of improving or supporting the diagnosis of or predicting/influencing the prognosis of CAA‐RI and to retrospectively evaluate different therapeutic approaches. Methods We present clinical and neuroradiological observations in seven unpublished CAA‐RI cases, including neuropathological findings in two definite cases. These cases were included in a systematic analysis of probable/definite CAA‐RI cases published in the literature up to 31 December 2021. Descriptive and associative analyses were performed, including a set of clinical, radiological and laboratory variables to predict short‐term, 6‐month and 1‐year outcomes and mortality, first on definite and second on an expanded probable/definite CAA‐RI cohort. Results Data on 205 definite and 100 probable cases were analysed. CAA‐RI had a younger symptomatic onset than non‐inflammatory CAA, without sex preference. Transmural histology was more likely to be associated with the co‐localisation of microbleeds with confluent white matter hyperintensities on magnetic resonance imaging (MRI). Incorporating leptomeningeal enhancement and/or sulcal non‐nulling on fluid‐attenuated inversion recovery (FLAIR) enhanced the sensitivity of the criteria. Cerebrospinal fluid pleocytosis was associated with a decreased probability of clinical improvement and longer term positive outcomes. Future lobar haemorrhage was associated with adverse outcomes, including mortality. Immunosuppression was associated with short‐term improvement, with less clear effects on long‐term outcomes. The superiority of high‐dose over low‐dose corticosteroids was not established. Conclusions This is the largest retrospective associative analysis of published CAA‐RI cases and the first to include an expanded probable/definite cohort to identify diagnostic/prognostic markers. We propose points for further crystallisation of the criteria and directions for future prospective studies. A systematic analysis of published and seven new cerebral amyloid angiopathy‐related inflammation (CAA‐RI) cases was performed. Incorporating leptomeningeal enhancement and/or sulcal non‐nulling on fluid‐attenuated inversion recovery (FLAIR) may improve the diagnostic sensitivity of the criteria. Cerebrospinal fluid pleocytosis was associated with decreased probability of clinical improvement and of positive outcomes. Future lobar intracerebral haemorrhage was associated with adverse outcomes, including mortality. Immunosuppression was associated with increased short‐term improvement. The superiority of high‐dose over low‐dose corticosteroids was not well established.
Bibliography:Funding information
Gabor G. Kovacs and Peter Klivenyi contributed equally to this study.
Dr Szalardy was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (Magyar Tudományos Akadémia) and the ÚNKP‐20‐5 New National Excellence Program of the Hungarian Ministry for Innovation and Technology from the source of the Hungarian National Research, Development and Innovation Fund (Nemzeti Kutatási, Fejlesztési és Innovaciós Alap). Dr Annus was supported by the National Talent Program (NTP‐NFTÖ‐21‐B‐0206). The study was supported by Grants TKP‐2021‐EGA‐32 provided by the Hungarian National Research, Development and Innovation Office (Nemzeti Kutatási Fejlesztési és Innovációs Hivatal) in the framework of the Thematic Excellence Programme 2021, 2017‐1‐1.1.2.1‐NKP‐2017‐0002 provided by the Hungarian National Research, Development and Innovation Office in the framework of the Hungarian National Brain Research Programme 2.0 and 5S 725 (A202) provided by the Albert Szent‐Györgyi Medical School, Albert Szent‐Györgyi Clinical Center, University of Szeged. The publication was supported by the University of Szeged Open Access Fund (Grant Number 5962).
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-5
ObjectType-Article-4
ObjectType-Report-1
ISSN:0305-1846
1365-2990
DOI:10.1111/nan.12946